Skip to main content
Premium Trial:

Request an Annual Quote

FedMed to Cover BioTheranostics Cancer MDx Tests

NEW YORK (GenomeWeb) – Genomic cancer diagnostic firm BioTheranostics today announced a contract with preferred provider organization FedMed to cover its tests for breast cancer and metastatic cancers.

As a result of the agreement, FedMed's 40 million covered lives will have access to San Diego-based BioTheranostics tests, including the Breast Cancer Index, which quantifies the risk of recurrence of early stage, estrogen receptor-positive breast cancer, as well as the BioT3 Metastatic Cancer Solution suite of tests, which provides diagnostic and therapeutic information for metastatic cancer patients.

The BioT3 Metastatic Cancer Solution tests include the CancerType ID molecular classifier for diagnosing tumor type and subtype, and the CancerTreatment ID, which uses next-generation sequencing and predictive biomarkers to identify appropriate treatment options.

Today's announcement is the latest in a string of agreements that BioTheranostics has recently reached with PPOs, including Prime Health Services and Three Rivers Provider Network.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.